95 related articles for article (PubMed ID: 22938478)
21. Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma.
Casella R; Shariat SF; Monoski MA; Lerner SP
Cancer; 2002 Dec; 95(12):2494-9. PubMed ID: 12467062
[TBL] [Abstract][Full Text] [Related]
22. Plasminogen Activation System in Rectal Adenocarcinoma.
Razik E; Kobierzycki C; Grzegrzolka J; Podhorska-Okolow M; Drag-Zalesinska M; Zabel M; Dziegiel P
Anticancer Res; 2015 Nov; 35(11):6009-15. PubMed ID: 26504024
[TBL] [Abstract][Full Text] [Related]
23. Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
Ljuca D; Fatusić Z; Iljazović E; Ahmetović B
Bosn J Basic Med Sci; 2007 May; 7(2):111-6. PubMed ID: 17489744
[TBL] [Abstract][Full Text] [Related]
24. Tissue urokinase-type plasminogen activator receptor levels in breast cancer.
Gong SJ; Rha SY; Chung HC; Yoo NC; Roh JK; Yang WI; Lee KS; Min JS; Kim BS; Chung HC
Int J Mol Med; 2000 Sep; 6(3):301-5. PubMed ID: 10934293
[TBL] [Abstract][Full Text] [Related]
25. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
26. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
[TBL] [Abstract][Full Text] [Related]
27. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
[TBL] [Abstract][Full Text] [Related]
28. [Expression of urokinase-type plasminogen activator and its receptor in plasma of patients with cerebral infarction].
Song SJ; Hu JB; Wang HX; Wen SQ; Ding MP; Huang JZ
Zhonghua Yi Xue Za Zhi; 2003 Sep; 83(18):1583-5. PubMed ID: 14642114
[TBL] [Abstract][Full Text] [Related]
29. Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR.
Almholt K; Lærum OD; Nielsen BS; Lund IK; Lund LR; Rømer J; Jögi A
Clin Exp Metastasis; 2015 Aug; 32(6):543-54. PubMed ID: 26040548
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.
Grøndahl-Hansen J; Peters HA; van Putten WL; Look MP; Pappot H; Rønne E; Dano K; Klijn JG; Brünner N; Foekens JA
Clin Cancer Res; 1995 Oct; 1(10):1079-87. PubMed ID: 9815897
[TBL] [Abstract][Full Text] [Related]
31. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
[TBL] [Abstract][Full Text] [Related]
32. [Expressions and clinical significance of urokinase-type plasminogen activator and its receptor in vulvar tissues].
Tian Y; Zhang XJ; Li GF; Wang W
Zhonghua Yi Xue Za Zhi; 2011 Sep; 91(35):2494-6. PubMed ID: 22321848
[TBL] [Abstract][Full Text] [Related]
33. [Expressions and clinical significance of urokinase-type activator (uPA) and uPA receptor (uPAR) in laryngeal squamous cell carcinoma].
Wang D; Wang T
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2005 Jun; 19(12):529-31. PubMed ID: 16176001
[TBL] [Abstract][Full Text] [Related]
34. [The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B].
Wu XR; Wang Q; Shi SS; Lu MH; Guo WD
Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):82-4. PubMed ID: 14980106
[TBL] [Abstract][Full Text] [Related]
35. Role of the urokinase plasminogen activator system in patients with bacterial meningitis.
Winkler F; Kastenbauer S; Koedel U; Pfister HW
Neurology; 2002 Nov; 59(9):1350-5. PubMed ID: 12427882
[TBL] [Abstract][Full Text] [Related]
36. Copenhagen uPAR prostate cancer (CuPCa) database: protocol and early results.
Lippert S; Berg KD; Høyer-Hansen G; Lund IK; Iversen P; Christensen IJ; Brasso K; Røder MA
Biomark Med; 2016; 10(2):209-16. PubMed ID: 26764285
[TBL] [Abstract][Full Text] [Related]
37. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
Jänicke F; Prechtl A; Thomssen C; Harbeck N; Meisner C; Untch M; Sweep CG; Selbmann HK; Graeff H; Schmitt M;
J Natl Cancer Inst; 2001 Jun; 93(12):913-20. PubMed ID: 11416112
[TBL] [Abstract][Full Text] [Related]
38. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
Meijer-van Gelder ME; Look MP; Peters HA; Schmitt M; Brünner N; Harbeck N; Klijn JG; Foekens JA
Cancer Res; 2004 Jul; 64(13):4563-8. PubMed ID: 15231667
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) for metastatic sentinel lymph node involvement in breast cancer.
Harms W; Malter W; Krämer S; Drebber U; Drzezga A; Schmidt M
Anticancer Res; 2014 Aug; 34(8):4457-62. PubMed ID: 25075085
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.
Dublin E; Hanby A; Patel NK; Liebman R; Barnes D
Am J Pathol; 2000 Oct; 157(4):1219-27. PubMed ID: 11021826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
